Which of the following represents the mechanism of action of GLP-1 agonists such as Semaglutide (Ozempic)

Rationale: A. Semaglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the incretin hormones that naturally regulate glucose metabolism. It enhances glucose-dependent insulin secretion, meaning it only triggers insulin release when blood sugar levels are high, which reduces the risk of hypoglycemia. Additionally, it suppresses the inappropriate postprandial secretion of glucagon, further lowering hepatic glucose output after meals. B. This description refers to the mechanism of SGLT-2 inhibitors, which work in the renal proximal tubules to block glucose reuptake. GLP-1 agonists do not have a primary direct effect on renal glucose transport or urinary excretion. While both drug classes are used in Type 2 diabetes, they target entirely different physiological systems to achieve glycemic control and cardiovascular protection. C. While GLP-1 agonists do stimulate insulin release, this simplified description is more characteristic of sulfonylureas, which provide glucose-independent stimulation. The defining feature of GLP-1 agonists is that their effect is glucose-dependent, providing a safer profile regarding low blood sugar. This nuanced distinction is critical for understanding the clinical benefits and safety parameters of semaglutide compared to older secretagogues. D. This is the primary mechanism of action for metformin, a biguanide. Metformin focuses on improving insulin sensitivity and reducing hepatic gluconeogenesis rather than directly stimulating insulin secretion or mimicking incretin hormones. GLP-1 agonists have a different therapeutic profile that includes delaying gastric emptying and increasing satiety, which contributes to the weight loss often seen with these agent